Characteristic | Total (%) (n = 166) | Outcome: non-fatal overdose, last 6 months | Odds ratio (95% CI) | |
---|---|---|---|---|
Yes (%) (n = 18) | No (%) (n = 144) | |||
Primary exposure | ||||
Experienced increased housing rules/surveillance during COVID-19 | 94 (56.6) | 15 (83.3) | 75 (52.1) | 4.60 (1.28–16.58) |
Demographics and living environment | ||||
Age (years; median, IQR) | 45 (36–52) | 48 (38–50) | 44 (36–52) | 1.01 (0.96–1.o6) |
Sexual minority | 76 (45.8) | 8 (44.4) | 66 (45.8) | 0.945 (0.35–2.53) |
Indigenous | 89 (53.6) | 11 (61.1) | 76 (52.8) | 1.32 (0.49–3.61) |
Lives in the DTESb | 64 (38.6) | 8 (44.4) | 55 (38.2) | 1.27 (0.47–3.40) |
Lives in supportive housinga | 109 (65.7) | 14 (77.8) | 92 (63.9) | 1.98 (0.62–6.32) |
Lives in a sheltera | 25 (15.1) | 5 (27.8) | 20 (13.9) | 2.39 (0.77–7.42) |
Feels in danger where currently sleeping | 57 (34.3) | 10 (55.6) | 45 (31.3) | 2.75 (1.02–7.43) |
Diagnosis/treatment/support for depression/anxiety/PTSDa | 42 (25.3) | 6 (33.3) | 36 (25.0) | 1.42 (0.50–4.05) |
Substance use patterns | ||||
Non-injection stimulantsa | 121 (72.9) | 16 (88.9) | 104 (72.2) | 3.08 (0.68–13.98) |
Non-injection opioidsa | 68 (41.0) | 10 (55.6) | 58 (40.3) | 1.83 (0.68–4.92) |
Injection stimulantsa | 58 (34.9) | 11 (61.1) | 46 (31.9) | 3.31 (1.21–9.10) |
Injection opioidsa | 73 (44.0) | 14 (77.8) | 59 (41.0) | 4.98 (1.56–15.90) |